Long-term safety and disease control with ruxolitinib cream among  patients with atopic dermatitis based on previous medication history:  Pooled results from two phase 3 studies

Andrew  Blauvelt; Lawrence Eichenfeld; Michael Kuligowski; May Venturanza; Kang Sun; Jonathan Silverberg

doi:10.25251/skin.5.supp.65

Andrew Blauvelt

Oregon Medical Research Center, Portland, OR, USA

Lawrence Eichenfeld

UC San Diego

Michael Kuligowski

Incyte Corporation, Wilmington, DE, USA

May Venturanza

Incyte Corporation, Wilmington, DE, USA

Kang Sun

Incyte Corporation, Wilmington, DE, USA

Jonathan Silverberg

George Washington University School of Medicine

Keywords

safety, ruxolitinib cream, atopic dermatitis, phase 3 study

Abstract

N/A

References

1. Langan SM, et al. Lancet. 2020;396(10247):345-360.

2. Eichenfield LF, et al. J Am Acad Dermatol. 2014;71(1):116-132.

3. Papp K, et al. J Am Acad Dermatol. 2021;85(4):863-872.

Poster PDF

Published

Nov 5, 2021

DOI https://doi.org/10.25251/skin.5.supp.65

How to Cite

Blauvelt, A. ., Eichenfeld, L., Kuligowski, M., Venturanza, M., Sun, K., & Silverberg, J. (2021). Long-term safety and disease control with ruxolitinib cream among patients with atopic dermatitis based on previous medication history: Pooled results from two phase 3 studies. SKIN The Journal of Cutaneous Medicine, 5(6), s65. https://doi.org/10.25251/skin.5.supp.65

Issue

Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

Section

Atopic Dermatitis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Richard Warren , April Armstrong , Melinda Gooderham, Bruce Strober , Diamant Thaci, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup , Sundeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Amy Paller, Andrew Blauvelt, Weily Soong, Shinichi Imafuku, Chih-ho Hong, Marie Schuttelaar, Petra Amoudruz, Azra Kurbasic, Lise Soldbro, Katja Lophaven, Michael Cork, Anthony Bewley, Eric Simpson, Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Andrew Blauvelt, Steven Kempers, Todd Schlesinger, Edward Lain, Hui Wang, David Cutler, Mark Lebwohl, Jane Fang, Rudolf Kwan, Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Pooled Data from Two Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Andrew Blauvelt, Steven Kempers, Seth Forman, Edward Lain, Suzanne Bruce, Tirbanibulin Ointment 1%, a Novel Inhibitor of Tubulin Polymerization and Src Kinase Signaling , for the Treatment of Actinic Keratosis (AK): Results from Two Pivotal Phase III Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Kim Papp, Jacek C. Szepietowski, Leon Kircik, Darryl Toth, Michael E. Kuligowski, May E. Venturanza, Kang Sun, Eric L. Simpson, Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Bruce Strober , Linda Stein Gold, Robert Bissonnette, April Armstrong , Andrew Blauvelt, Philip Brown, Leon Kircik, Anna Tallman, Mark Lebwohl, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Bruce Strober , Linda Stein Gold, Robert Bissonnette, April Armstrong , Andrew Blauvelt, Leon Kircik, Philip Brown, Anna Tallman, Mark Lebwohl, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Andrew Blauvelt, Diamant Thaci, Kim Papp, Vincent Ho, Kamran Ghoreschi, Byung Soo Kim, Megan Miller, Yaung-Kaung Shen, Yin You, Jenny Yu, Ya-Wen Yang, Jeffrey Crowley, Peter Foley, Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2 , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Linda Stein Gold, Andrew Blauvelt, April Armstrong , Seemal Desai, Howard Sofen, Lawrence Green, Steve Tyring, Laura Ferris, Philip Brown, David Rubenstein, Stephen Piscitelli, Anna Tallman, Leon Kircik, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Andrew Blauvelt, Phoebe Rich, Howard Sofen, Jo Lambert, Joe Merola, Mark Lebwohl, Lauren Hippeli, Renata Kisa, Subhashis Banerjee, Alexa Kimball, Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 4 (2022): July 2022 Issue

1 2 3 4 5 6 7 8 9 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)